Agustin A. García

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

Agustin A. García, Hal W. Hirte, Gini F. Fleming et al. · Journal of Clinical Oncology · 2007 · 547 citations

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. · New England Journal of Medicine · 2015 · 530 citations · Full text

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Michael S. Gordon, Daniela Matei, Carol Aghajanian et al. · Journal of Clinical Oncology · 2006 · 249 citations

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, Robert P. Edwards et al. · International Journal of Gynecological Cancer · 2005 · 221 citations

Safety and feasibility of fasting in combination with platinum-based chemotherapy

Tanya B. Dorff, Susan Groshen, Agustin A. García et al. · BMC Cancer · 2016 · 207 citations · Full text